Voss, Martin H <br/><br/>
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring   [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  05 2019 
 - 2699-2707 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-18-1959  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzimidazoles--pharmacokinetics<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Gene Fusion<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Mutation<br/>Neoplasms--drug therapy<br/>Prognosis<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Pyrazoles--pharmacokinetics<br/>Receptor, Fibroblast Growth Factor, Type 1--antagonists & inhibitors<br/>Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors<br/>Receptor, Fibroblast Growth Factor, Type 3--antagonists & inhibitors<br/>Signal Transduction<br/>Tissue Distribution